Vical Incorporated Release: Publication Highlights Allovectin-7(R) Phase 2 Safety and Efficacy Results in Melanoma

SAN DIEGO, Jan. 11, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced a new publication summarizing results from the company's completed trials of Allovectin-7® including systemic responses and an excellent safety profile in patients with metastatic melanoma. An article published in the January issue of Immunotherapy1 noted that the U.S. incidence of melanoma is increasing rapidly, that current therapies are inadequate and toxic, and that melanoma is responsive to immune-stimulating drugs like Allovectin-7®. A Phase 3 trial evaluating the safety and efficacy of Allovectin-7® compared with standard chemotherapy is expected to complete final follow-ups later this year.